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we can estimate if early therapy of early diagnosed very small cystic 
lesions results in longer survival for our patients or if follow-up 
strategies are recommended. These data is actually missing, and 
further studies are needed. A second point is that a wide dissemi-
nation of the knowledge of diagnostic and therapeutic algorithms 
will increase the overall number of identified cystic pancreatic le-
sions in non-pancreatic cancer centers. These two facts could over-
whelm today’s capacities, and a steady state will not be reached.
Hackert: Judging from the development during the last decade, 
it seems likely that cystic lesions will have a further increasing im-
pact in the future. The fact that modern imaging modalities offer 
excellent results in terms of abdominal imaging will lead to an even 
higher number of accidentally diagnosed cysts than observed 
today. Therefore, the management of these patients will be an even 
more important topic. With regard to symptomatic cystic lesions, 
we may have reached a steady state already.
Mayerle: With an increasing sensitivity of imaging techniques 
such as secretin-stimulated magnetic resonance imaging (MRI) we 
are detecting an increasing number of cystic lesions of the pancreas 
in a range between 1.2% (computed tomography (CT) scan) and 
27.7% (secretin-enhanced MRI) in asymptomatic patients or vol-
unteers with a significant increase in prevalence in elderly cohorts 
[4]. In a cohort of 300 elderly patients (more than 80% older than 
65 years), an autopsy study as gold standard reported a prevalence 
of 24.3% of pancreatic cysts, suggesting that modern imaging tech-
niques are detecting 100% of pancreatic cystic lesions [5]. The me-
dian size of cysts detected is 8 mm, and 12–15% of pancreatic cystic 
lesions occurred at multiple sites. Our own data show that 69% of 
all cysts in 2,088 healthy volunteers were below 5 mm in diameter, 
26% below 1 cm, and only 5.3% of all patients with cystic lesions or 
Question 1: Will the impact of cystic pancreatic  
lesions in daily practice further increase in the 
 future or have we reached a steady state already?
Esposito: The frequency of incidentally detected cystic lesions 
of the pancreas has substantially increased in the past years due to 
the increased sensitivity of detection methods. However, most of 
these lesions are <1 cm [1] and of unknown clinical relevance. 
Small, primarily cystic lesions (i.e. not resulting from degeneration 
of solid neoplasms, which occurs when the lesion attains a larger 
size) with malignant potential include intraductal papillary muci-
nous neoplasms (IPMN), mucinous cystic neoplasms (MCN), 
cystic neuroendocrine tumors (NET), and rare cystic mesenchy-
mal neoplasms. There is no recent autopsy study addressing the 
histological characterization of incidental, small cystic lesions and 
incorporating the current classifications as well as the present 
knowledge, especially concerning their molecular physiopathology 
and natural history [2, 3]. Performing such a study would help in 
answering the question of the impact of cystic pancreatic lesions 
from the point of view of both their overall frequency and their 
clinical relevance.
Grenacher: In pancreatic cancer centers with a high level of 
knowledge, combined with optimized multidisciplinary imaging 
techniques (experienced endosonography, high spatial resolution 
scanners below 1 mm, and optimized protocols), we detect inci-
dental cystic lesions of the pancreas below 1 mm in size in our daily 
routine, and this fact has reached a level that will only slightly in-
crease in the near future. The impact of these lesions for our thera-
peutic strategies is difficult to estimate for the future because we 
are at the beginning of our learning curve for the estimation of ma-
lignancy of these lesions. Only when we have evidence-based data 
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1.3% of all volunteers were found to have cysts larger than 10 mm 
(n = 28/2,088) [6]. In autopsy studies, only 20% of cystic pancreatic 
lesions represent IPMNs and as such have to be regarded as prema-
lignant lesions. The mere presence of pancreatic cysts does not an-
swer the question of their clinical relevance.
Question 2: What is the essence for the general 
practitioner regarding cystic pancreatic lesions? 
Age-dependent screening for all, examinations only 
for symptomatic patients, or can risk populations 
be defined?
Esposito: Although the likelihood of having an incidental cystic 
pancreatic lesion increases with age [1, 5, 7], age-based screening is 
not evidence-supported so far. In fact, as stated above, the natural 
history and the histologic type of these incidental lesions is largely 
unknown. Moreover, the definition of risk populations is limited to 
cases of familial pancreatic cancer or other rare genetic syndromes 
(p16-Leiden, McCune-Albright, von Hippel-Lindau) where cystic 
pancreatic neoplasms with different biological behavior and malig-
nant potential can occur [8]. The referral of patients with inciden-
tal cystic pancreatic lesions to specialized centers for further inves-
tigations seems therefore appropriate. 
Grenacher: As already mentioned above, besides defining strate-
gies based on evidence-based data I am absolutely sure that in the 
near future we will come to an image-based characterization of po-
tential malignancy of cystic lesions, especially IPMNs and their 
subtypes.
Hackert: The essence for the general practitioner at the moment 
is certainly not to perform screening examinations as we do not yet 
have valid criteria for whom to screen. Today, it is important that 
all general practitioners, regardless of their subspecialization, are 
aware of the existence and malignant potential of pancreatic cysts. 
In the case of diagnosis of a cystic tumor in one of their patients, 
the management should be coordinated with a specialized pancre-
atic center – unless the general practitioner himself already has ex-
tensive experience with these lesions. The most important aim at 
the moment is to create awareness for cystic lesions and to encour-
age the presentation of the findings and/or the patient to an expert. 
Therefore, a sufficient number of centers and contact persons are 
required to facilitate this intercollegiate dialogue.
Mayerle: Until today, there are no data indicating a benefit for 
the patients’ survival if asymptomatic individuals are screened for a 
cystic pancreatic lesion. Furthermore, we have no data supporting 
that earlier diagnosis or aggressive treatment results in increased 
survival or is cost-effective. Examination and follow-up of sympto-
matic patients or incidental cysts is justified on the background 
that 2.9% of the cases with a non-inflammatory cystic lesion are 
diagnosed with a pancreatic malignancy. However, the majority 
(74%) of malignant cystic pancreatic lesions is detected at the time 
of cyst diagnosis, and those are only asymptomatic in a minority of 
cases. The incidence of malignant transformation of a non-inflam-
matory cystic pancreatic neoplasm is 0.4% per year. The prevalence 
rate of mucin-producing adenocarcinoma arising in patients with 
pancreatic cysts is 32.8/100,000 population. The overall age- and 
gender-adjusted standardized incidence ratio of pancreatic malig-
nancy in this cohort is 35 times greater than that of the general 
(non-cyst) population. This increased risk for pancreatic cancer 
justifies surveillance of patients with a cystic pancreatic lesion [9]. 
An obvious, but rare risk cohort for IPMN is patients suffering 
from McCune-Albright syndrome with germline GNAS mutations. 
Recently, IPMNs have been described as a McCune-Albright syn-
drome-associated tumor, present in about 15% of the patients [10]. 
In familial pancreatic cancer families, cystic lesions of the pancreas 
are more common (42%). IPMNs can be found in 33% of the pa-
tients with familial polyposis coli (FPC) in the surroundings of 
pancreatic cancer resection specimens while they are present in 
only 6% of resection specimens from sporadic pancreatic cancer 
patients. Thus, in FPC patients IPMNs need to be considered as 
indicator lesion for pancreatic cancer [8]. In case of diagnosis of a 
pancreatic cystic lesion, the recommendation for the general prac-
titioners is to refer the patient to a specialized center.
Question 3: Which high-risk features of  
precancerous pancreas lesions are the most valid 
and important ones?
Grenacher: Beside the statements of my interdisciplinary col-
leagues I want to add that we have already started with functional 
imaging (so-called diffusion-weighted MRI (DW-MRI)) to analyze 
the viscosity of the intraductal mucin of the different types of 
IPMN as a potentially relevant cofactor for the prediction of malig-
nancy. The future will then show us if the difficult search for iden-
tifying intraductal nodules could be abandoned.
Hackert: Currently, probably symptoms, elevated serum carbo-
hydrate antigen (CA) 19-9, and solid components in the imaging 
seem to be the most reliable features, as well as a growth tendency 
in the follow-up. The size of a lesion itself does not seem to be a 
sufficient parameter, especially in branch-duct IPMN. The discus-
sion about a cut-off of 2 or 3 cm in these lesions as a criterion for 
surgery and the controversy about the malignancy risk correlated 
with these thresholds underline the insufficiency of size alone. 
Therefore, more precise parameters are urgently needed to im-
prove this grey area of management recommendations to achieve 
more evidence-based consensus statements and guidelines in the 
future.
Mayerle: The risk of malignancy in main-duct IPMN is up to 
95.8%, justifying resection at all costs. For side-branch IPMN, in 
addition to the Sendai criteria, the Fukuoka criteria suggest that 
high-risk stigmata or worrisome features such as obstructive jaun-
dice in a patient with cystic lesion of the head of the pancreas, en-
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hancing solid component within cysts, main pancreatic duct >10 
mm in size or pancreatitis, a cyst >3 cm, thickened/enhancing cyst 
walls, main duct size of 5–9 mm, non-enhancing mural nodule, 
and abrupt change in caliber of pancreatic duct with distal pancre-
atic atrophy are associated with an increased risk of malignancy, 
and this has been confirmed in independent studies [11]. The rate 
of pancreatic cancer in patients with a Sendai-negative side-branch 
IPMN is given with 1 in 500 (0.26%). Nodules >5 mm (or >10 mm 
[12]) are regarded as the best predictor of malignancy. However, 
even in the presence of nodules the rate of malignancy in resected 
branch-duct IPMN is below 30% [13]. As size is a less accurate pre-
dictor of malignancy, cysts with a diameter above 2 cm should be 
surveyed with care to be on the safe side [13].
Question 4: In case of surveillance – which tests, 
which imaging modalities, which intervals should 
be chosen?
Esposito: Both questions 3 and 4 are better answered by col-
leagues from clinical disciplines. However, as a pathologist, I 
would like to add a few considerations which may prove useful to 
refine the recommendations for surveillance and/or treatment of 
cystic pancreatic lesions in the future [2]. According to some re-
cent large surgical series, which include resected cystic lesions 
from both asymptomatic (i.e. incidentally discovered) and symp-
tomatic patients [14, 15], the following entities largely predomi-
nate: IPMN, MCN, serous cystic neoplasms (SCN), and cystic 
neuroendocrine neoplasms (cNEN). Of these, only SCN are al-
most entirely benign and without risk of progression. IPMN, 
MCN, and cNEN are all potentially malignant, but with different 
biological risks of progression. IPMN and MCN are precursors of 
invasive carcinoma. However, among main-duct IPMN, only the 
pancreatobiliary subtype is usually a high-grade (in situ or already 
invasive) lesion at diagnosis, therefore warranting resection. The 
more common intestinal subtype displays low-grade features at 
diagnosis in about 50% of the cases; moreover, due to its associa-
tion with the colloid type of invasive cancer and not with classical 
pancreatic ductal adenocarcinoma, it can be considered a lesion 
with a low biological risk of progression. Gastric-type IPMN 
largely predominates in the branch-duct IPMN category and is in 
most cases a low-grade lesion at diagnosis. MCN can be also con-
sidered as lesions with low biological risk, since they are slowly 
growing tumors with usually low incidence of invasive cancer. 
NEN are all potentially malignant. However, cNEN usually belong 
to the NET category (i.e. G1 and G2 tumors), i.e. tumors with 
maximally low-grade malignant behavior, and are biologically less 
aggressive than solid NET [16].
These considerations imply that a careful histological charac-
terization and subtyping, aided by the use of routine ancillary 
methods such as immunohistochemistry, can assist in further strat-
ification and – possibly – better clinical management of cystic pan-
creatic lesions. Moreover, the identification of additional molecu-
lar markers, e.g. through deep-sequencing-based analyses of tumor 
subtypes for the prediction of high-risk biological behavior, might 
help in refining the current strategies of management of these le-
sions in the future.
Hackert: The practical performance of surveillance, if indicated, 
is certainly depending on the experience of the respective center. 
Besides investigation of the patient and the clinical examination, a 
blood test for the routine parameters including pancreas and liver 
parameters as well as the tumor markers carcinoembryonic antigen 
(CEA) and especially CA 19-9 is recommendable. For surveillance 
imaging, endoscopic ultrasound (EUS) and MRI seem to be the 
methods of choice to avoid recurrent X-ray exposition by CT 
scans. EUS and MRI seem to be equally effective if the examiner-
dependent experience level is sufficiently high in a center. Espe-
cially for EUS, this is crucial to allow a precise evaluation of the 
cystic lesion and of the changes in the surveillance course. For MRI 
surveillance, technical conditions should allow a thin-slice imaging 
and an inclusion of an MRCP (magnetic resonance cholangiopan-
creatography) sequence, e.g. in an ‘all-in-one’ protocol. If both mo-
dalities are present with similar expertise in a center and there are 
no patient-related contraindications to one of them, the modality 
should be chosen in agreement with the patient, who may prefer 
one or the other. Intervals of screening are practically chosen be-
tween 3 and 12 months according to the ‘surveillance state’ of the 
cystic lesion. This implies that after initial diagnosis and decision 
for surveillance a short interval of 3 months is advisable to charac-
terize growth behavior. In case of unchanged features of the lesion, 
6 months can be chosen for the next follow-up period if no worri-
some features are present. In the long-term surveillance, which is 
only advisable for cystic lesions without any worrisome features 
anyway, annual examinations seem to be sufficient.
Mayerle: The decision to follow an IPMN is a matter of clinical 
judgment based on patient age, family history, symptoms, comor-
bidities, perceived pancreatic cancer risk, and patient preference. 
We have to keep in mind that the prevalence of cystic pancreatic 
lesions is 10% in patients above the age of 80 years and that those 
occur at multiple sites as a field defect in 10–15%. Furthermore, in 
this cohort only a minority will die from pancreatic cancer if all-
cause mortality is considered. At baseline, history/physical exami-
nation and MRI/MRCP or EUS should be performed. MRCP has a 
sensitivity of 91.4–100.0% and a specificity of 89.7% to detect a 
duct connection of the cystic lesion while EUS is the most sensitive 
method for detecting the presence of mural nodules [17]. For sur-
veillance, patients without ‘high-risk stigmata’ should undergo 
short-interval (3–6 months) pancreatic MRI/MRCP or EUS to es-
tablish the static behavior of the cystic lesion, if prior imaging is 
not available. Subsequently, surveillance should be stratified with 
regard to the size of the lesion. The precise algorithm can be found 
in the Fukuoka guidelines [18]. There is no evidence that patients 
are endangered when following those guidelines. Surgically fit pa-
tients with ‘high-risk stigmata’ detected on surveillance should un-
dergo resection. Shorter surveillance intervals (3–9 months) should 
be considered in patients whose IPMN progresses toward these in-
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dicators or patients who already have ‘high-risk stigmata’ and, for 
reasons of operative risk or personal preference, have chosen sur-
veillance over resection. The issue of whether a rapid growth rate is 
correlated with an increased risk of malignancy remains unclear; 
however, shorter surveillance intervals are recommended in such 
patients [11]. 
Grenacher: I completely agree with the answer of Professor 
Mayerle. For follow-up surveillance with the proviso for patient 
comfort, I would prefer the non-invasive method of MRI including 
MRCP prior to EUS.
Question 5: Which impact does EUS-guided or  
percutaneous biopsy have on decision making?
Esposito: As discussed above, histological analysis and routine 
immunohistochemical characterization (e.g. MUC1, MUC2, 
MUC5A for IPMN; synaptophysin and Ki-67 for cNEN; beta-
catenin for solid pseudopapillary neoplasms (SPN); MUC6 and in-
hibin for SCN) as well as molecular tests (GNAS for IPMN, 
CTNNB1 for SPN) can provide important information concerning 
diagnosis and, partly, risk stratification [19]. However, technical is-
sues as well as the experience of both the clinician performing the 
fine needle aspiration and the pathologist evaluating the specimens 
are critical factors for achieving higher sensitivity and specificity 
rates. In the hands of experts, this technique has an important im-
pact on the decision making process. The development of molecu-
lar tests is going to further improve the diagnostic accuracy in the 
near future [20].
Hackert: The performance of any cyst fluid, cytology, or biopsy 
analysis – either EUS-guided or percutaneously – is not routinely 
recommendable. CEA in cyst fluids has not proven to be a useful 
marker for the differentiation between benign and malignant le-
sions, and neither have any other fluid markers yet. Cytology or 
biopsy may be useful in highly selected patients as well as in centers 
with great experience in the pathological work-up of these samples. 
Besides a maximum accuracy of about 80% for malignancy predic-
tion, the potential danger of spilling cyst content with the conse-
quence of dissemination of tumor cells needs to be considered. 
Therefore, especially the puncturing of cysts with worrisome fea-
tures seems to be critical and should be avoided.
Mayerle: Elevated CEA in the cyst aspirate is a marker that dis-
tinguishes mucinous, premalignant from non-mucinous, benign 
lesions, but not benign from malignant cysts. A cut-off of 400 ng/
ml improves the specificity at the expense of the sensitivity. A low 
CEA level does not exclude a mucinous cyst. Cyst fluid lipase is not 
uniformly elevated in IPMN, and MCN may also exhibit elevated 
lipase levels. Serous cysts typically have low levels of both CEA and 
lipase. Cytology can be diagnostic, although the sensitivity is lim-
ited by the scant cellularity. In summary, interpreting the results of 
biochemical markers in cyst fluid is a complex exercise in pattern 
recognition and should be reserved for patients in whom addi-
tional information will have an impact on the surgical decision 
making [21].
Question 6: Should surveillance, treatment, and  
follow-up of precancerous lesions of the pancreas  
be further centralized in Germany?
Esposito: Yes, for the reasons outlined above.
Grenacher: Yes, for the reasons given in this discussion.
Hackert: Probably more important than more centralization is 
the aim of creating the required expertise in additional places. As 
the number of patients with cystic lesions kept under surveillance, 
treated, and followed-up is likely to increase, center experience is 
increasingly required. This does not imply keeping or reducing the 
number of centers with the aim of more patients in less centers, but 
the creation of high-quality centers in more places to facilitate ac-
cess to the centers for the respective patients and cooperating 
practitioners.
Mayerle: As outlined above, diagnosis and surveillance of cystic 
pancreatic lesions is a complex exercise in pattern recognition and 
thus should be in the hands of experts.
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